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Introduction
Acute pain is physiologically significant and serves as a danger alarm to the body, while chronic pain exhibits a disease nature and should be prevented (Costigan et al., 2009 ). Chronic pain is often accompanied by emotional disorders that lead to different types of pain states (Seymour and Dolan, 2013) , implying the presence of a vicious cycle of pain (Costigan et al., 2009) . Neuropathic pain, a representative chronic pain, occurs following damage of pain pathways from the periphery to the brain (Costigan et al., 2009) , and is clearly distinguished from nociceptive pain in terms of its nature, which is characterized by hyperalgesia and allodynia (Baron, 2006) . Since the establishment of animal models for neuropathic pain in the late 1980s (Bennett and Xie, 1988; Ossipov and Porreca, 2013) , extensive studies of neuronal plasticity, based on physiological and anatomical characterization (Basbaum et al., 2009; Devor, 2013) , and molecular biological studies, based on identification of key molecules, have contributed to the better understanding and research development of therapeutics (Ueda, 2006; Ueda, 2008; Costigan et al., 2009; Kuner, 2010; Hill, 2013) .
Central pain, which is closely related to the emotional disturbance, has been poorly characterized, because it is unclear which parts of the pain-regulatory system are disordered. Fibromyalgia, an intractable generalized pain syndrome, is known to comprise an approximately 2% population ratio in developed countries (Russell, 2013; Clauw, 2014) . Limited etiology information of fibromyalgia, a representative central pain, delays the reasonable diagnosis and therapy (Russell, 2013; Clauw, 2014) . Basic studies using animal models, which mimic symptoms or pharmacotherapeutical sensitivities in fibromyalgia patients, would be essential for advancing diagnosis or This article has not been copyedited and formatted. The final version may differ from this version.
JPET Fast Forward. Published on March 24, 2015 as DOI: 10.1124 at ASPET Journals on November 5, 2016 jpet.aspetjournals.org Downloaded from JPET #222414 5 therapy. To establish animal models of fibromyalgia, Levine's group has used subdiaphragmatic vagotomy (Khasar et al., 2003) , while Sluka's group has used repeated intramuscular injections of acidic saline (Sluka et al., 2001 ). There are also several unique models induced by reserpine treatment (Nagakura et al., 2009 ) and intermittent sound stress (Khasar et al., 2009) . These animal models share some pathophysiological or behavioral features with fibromyalgia patients (DeSantana et al., 2013) . Additionally, we have reported another fibromyalgia-like pain model caused by intermittent cold stress (ICS) (Nishiyori and Ueda, 2008) . This model has shown characteristics of a generalized chronic pain phenotype and shares female-predominant sex differences and pharmacotherapeutic features with fibromyalgia patients. Specifically, ICS-induced pain is sensitive to gabapentin and antidepressants (Nishiyori and Ueda, 2008; Nishiyori et al., 2011) , but not to morphine (Nishiyori et al., 2010) , which is consistent with the clinical evidence of fibromyalgia patients (Clauw, 2014) .
Currently, the therapy for chronic pain, such as neuropathic pain and fibromyalgia, has predominantly included the use of existing analgesics and analgesic adjuvants (Arnold, 2009; Toelle and Backonja 2013) . The rationale for using analgesic adjuvants, despite a poor understanding of mechanisms underlying fibromyalgia, is based on the remedy of somatic symptoms. However, because of insufficient therapeutic actions and adverse effects, the therapeutic strategies have not been established (Smith et al., 2011) .
According to the new guidelines approved by the American College of Rheumatology (Russell, 2013; Clauw, 2014) , the criteria for fibromyalgia include severity of somatic symptoms as well as widespread pain. In line with the current situation for chronic pain control, we focused on the muscarinic agonist pilocarpine, which inhibits dry-eye and dry-mouth, which are often observed in fibromyalgia patients (Bennett, 2005) . Here, we This article has not been copyedited and formatted. The final version may differ from this version. 
Materials and Methods
Animals. Male C57BL/6J mice (TEXAM Corporation, Nagasaki, Japan), weighing 20-25 g, were used for the present study. The mice were housed in a room with a temperature of 22 ± 3°C with free access to a standard laboratory diet and tap water. All procedures used in this work were approved by the Nagasaki University Animal Care Committee, and complied with the fundamental guidelines for the proper conduct of animal experiments and related activities in academic research institutions under the jurisdiction of the Ministry of Education, Culture, Sports, Science and Technology, Japan.
Drug treatments. Pilocarpine was purchased from Wako (Osaka, Japan), while donepezil, atropine, and pirenzepine were obtained from Sigma-Aldrich (St. Louis, MO, USA). These drugs were dissolved in physiological saline for intraperitoneal (i.p.) injection or in artificial cerebrospinal fluid (aCSF; 125 mM NaCl, 3.8 mM KCl, 1.2 mM KH 2 PO 4 , 26 mM NaHCO 3 , 10 mM glucose, pH 7.4) for intrathecal (i.t.) and intracerebroventricular (i.c.v.) injection. Pirenzepine was injected 10 min prior to pilocarpine injection, while atropine was administrated 10 min prior to donepezil injection. Morphine hydrochloride (Takeda Chemical Industries, Osaka, Japan) was dissolved in aCSF. The i.t. injection was given into the space between spinal L5 and L6 segments, according to the method described by Hylden and Wilcox (Hylden and Wilcox, 1980) . Intermittent cold stress exposure. Mice were exposed to ICS, as previously described (Nishiyori and Ueda, 2008) . Briefly, mice were placed in a cold room at 4°C overnight (from 4:30 pm to 10:00 am), followed by ICS with alternating environmental This article has not been copyedited and formatted. The final version may differ from this version. procedures were repeated twice. On day 3, the mice were returned to and adapted to a room temperature of 24°C for 1 h before the nociception tests. We designated day 3 following the onset of stress exposure as day 1 post-stress exposure (P1). Mice in the control group were maintained at 24°C for all 3 days (from 4:30 pm on day 1 to 10:00 am on day 3). During the stress period, two mice were kept in each cage (12 × 15 × 10.5 cm), with free access to food and agar in place of fluid.
Nociception tests. In the thermal paw withdrawal tests, the nociception threshold was determined by the latency of paw withdrawal upon a thermal stimulus (Uchida et al., 2010) . Non-anesthetized animals were placed in Plexiglas cages on top of a glass sheet, and an adaptation period of 1 h was allowed. The thermal stimulator (IITC Inc., Woodland Hills, CA, USA) was positioned under the glass sheet, and the focus of the projection bulb was aimed directly at the middle of the plantar surface of the animal. A mirror attached to the stimulator permitted visualization of the plantar surface. A cut-off time of 20 s was set to avoid tissue damage. The mechanical paw pressure test was performed as previously described (Uchida et al., 2010) . Briefly, mice were placed in a Plexiglas chamber on a 6 × 6 mm wire mesh-grid floor and allowed to acclimatize for a period of 1 h. A mechanical stimulus was then delivered to the middle of the plantar surface of the right hindpaw using a Transducer Indicator (Model 1601; IITC Inc.). The pressure needed to induce a flexor response was defined as the pain threshold. A cutoff pressure of 20 g was set to avoid tissue damage. In experiments using mechanical and thermal tests, the thresholds were determined from three repeated challenges at 10-min intervals, and the response averages were evaluated. An electrical, stimulation-induced paw withdrawal test was performed as previously described (Uchida et al., 2010) . post-stress exposure (Nishiyori et al., 2010) . Thermal hyperalgesia lasts for at least 15 days, whereas constant cold stress decreases the threshold to 6 s at P1, and hyperalgesia disappears at P5 (Nishiyori and Ueda, 2008; Nishiyori et al., 2010) . Therefore, we Indeed, we found that the pilocarpine (1 mg/kg, i.p.)-induced anti-hyperalgesic effect was markedly blocked by i.c.v. injection of pirenzepine (1 μg), an antagonist of muscarinic acetylcholine receptor ( Fig. 2D ; F 3 = 26.6; **p < 0.01, ## p < 0.01).
Donepezil reverses ICS-induced pain via supra-spinal actions.
The above findings prompted us to investigate whether similar beneficial effects were observed with donepezil, which readily penetrates into the brain (Banks, 2012) . When doses of donepezil as low as 10 μg/kg were i.p. administered to ICS-treated mice,
anti-hyperalgesic actions of this compound were observed with peak effects at 90-120 min post-injection ( Fig. 3A ; 0 h, F 3 = 120.4; 0.5 h, F 3 = 18.8; 1 h, F 3 = 15.4; 1.5 h, F 3 =14.7; 2 h, F 3 = 12.4; 2.5 h, F 3 = 13.8; 3 h, F 3 = 16.0; **p < 0.01, # p < 0.05, ## p < 0.01).
This article has not been copyedited and formatted. The final version may differ from this version. Some, although not significant, anti-hyperalgesic effects still remained even at 180 min (Fig. 3A) . There was a dose-dependent range of 1-100 μg/kg, with an ED 50 as low as 2 μg/kg ( Fig. 3B ; F 6 = 9.4; **p < 0.01, ## p < 0.01). Similar results were also observed in the mechanical nociception test ( Fig. 3C ; 0 h, F 3 = 49.0; 0.5 h, F 3 = 7.2; 1 h, F 3 = 12.0;
1.5 h, F 3 = 11.0; 2 h, F 3 = 5.0; 2.5 h, F 3 = 13.8; 3 h, F 3 = 8.9; *p < 0.05, **p < 0.01, Complete cure of chronic pain by repeated treatments with donepezil. Based on the long-lasting effects of donepezil by systemic or i.c.v. injection, we examined the possibility of accumulative donepezil effects. In the present paradigm, donepezil was administered at a dose of 10 μg/kg (i.p.) once daily from P5 to P10. As seen in Fig. 4A (0 h at P5, F 3 = 120.4; 0.5 h at P5, F 3 = 18.8; 1 h at P5, F 3 = 15.4; 1.5 h at P5, F 3 =14.7; 2 h at P5, F 3 = 12.4; 2.5 h at P5, F 3 = 13.8; 3 h at P5, F 3 = 16.0; 0 h at P7, F 3 = 88.5; 0.5 h at P7, F 3 = 17.6; 1 h at P7, F 3 = 17.4; 1.5 h at P7, F 3 = 9.7; 2 h at P7, F 3 = 18.3; 2.5 h at P7, F 3 = 9.6; 3 h at P7, F 3 = 15.0; 0 h at P9, F 3 = 32.7; 0.5 h at P9, F 3 = 13.4; 1 h at P9, F 3 = 19.6; 1.5 h at P9, F 3 = 11.1; 2 h at P9, In experiments using ICS mice, however, the basal nociceptive threshold at P7 was significantly greater than the basal threshold on P5 (Fig.   4B ). The acute anti-hyperalgesia effects of donepezil were still observed, but the maximum threshold never exceeded the naive threshold (Fig. 4A ). This fact resulted in some decrease in the acute anti-hyperalgesia effects, which were evaluated by area under the curve ( Fig. 4C ; F 5 = 32.2; **p < 0.01). Similar results were also observed with donepezil injection at P9 (Fig. 4C ). In addition, the basal threshold at P11 reached approximately 10 s, which corresponds to the threshold of naive mice (Fig. 4B ).
When the basal thresholds prior to donepezil injection were plotted, they gradually increased along with daily injection of donepezil (six times from P5 to P10), as shown in Figure 4B . The basal thresholds from P11 to P18, even after cessation of donepezil treatments, were similar to the naive level (Fig. 4B ). Repeated treatments with donepezil showed no significant changes in the basal threshold of control mice (Fig.   4B ). When mechanical allodynia effects were evaluated instead of thermal hyperalgesia, the basal thresholds of ICS-treated mice at P1 through P18 were significantly less than the control ( Fig. 4D ; P1, F 3 = 47.7; P12, F 3 = 13.8; P18, F 3 = 22.9; **p < 0.01, ## p < 0.01). Repeated treatments with donepezil completely reversed mechanical allodynia at P12 and P18 in ICS-treated mice, but these treatments had no effect on basal mechanical threshold in control mice ( control-donepezil-morphine, F 3 = 9.7; *p < 0.05, **p < 0.01).
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Discussion
In the present study, we used an ICS model to replicate a unique, generalized, chronic pain syndrome, which includes fibromyalgia. Our previous study has shown that ICS triggers chronic and bilateral thermal hyperalgesia, as well as mechanical allodynia (Nishiyori and Ueda, 2008) . ICS-induced hyperalgesia and allodynia is specific for intermittent stress, because pain hypersensitivity against thermal and mechanical stimuli can be observed for only 1 day after constant cold stress (Nishiyori and Ueda, 2008; Nishiyori et al., 2010) . Although there is no significant difference in the basal pain threshold between male and female mice, significant female-predominant sex differences in mechanical allodynia can be observed (Nishiyori and Ueda, 2008) .
Compared with other experimental fibromyalgia-like pain models, the ICS model appears to have several advantages in terms of pharmacotherapeutic responses, or their description in terms of similarity to clinical evidence.
First, the gabapentin dose required for the suppression of ICS-induced mechanical allodynia is 10 times less than that for the partial sciatic nerve ligation-induced neuropathic pain (Nishiyori and Ueda, 2008) . Interestingly, i.c.v. injection of gabapentin as low as 3 μg completely inhibits ICS-induced allodynia for 2 days, and significant anti-allodynia effects last at least for 4 days, whereas i.c.v. injection of gabapentin has no significant action on neuropathic pain (Nishiyori and Ueda, 2008) . Similar differences between ICS and injury models can be observed in the analgesic action of morphine. The analgesic effects of systemically administered morphine is 10 times less potent in nerve injury-induced neuropathic pain model mice, but is completely lost in the ICS model (Nishiyori et al., 2010) . Clinical evidence has also shown that opioids are ineffective in suppressing pain in fibromyalgia patients (Clauw, 2014) . One of the underlying mechanisms could be attributed to reduced availability of opioid receptors in the brain (Harris et al., 2007) , possibly owing to excess amounts of endogenous opioids in the CSF of fibromyalgia patients (Baraniuk et al., 2004) . The reduced sensitivity to morphine in the ICS model may be related to functional deficits in the descending serotonergic activity (Ohara et al., 1991; Omiya et al., 2000; Nishiyori et al., 2010) , which is consistent with biochemical evidence in clinical samples (Clauw, 2009 ).
Our initial intention was to use various existing drugs that have some indications for fibromyalgia patients. Pilocarpine is the representative drug used to treat dry-eye and dry-mouth, which are often observed in fibromyalgia patients (Bennett, 2005) . was administered by i.c.v. injection, but not by i.t. injection, which suggests that major sites of muscarinic receptor-mediated actions are in the brain.
To further assess the role of central cholinergic systems in fibromyalgia pain, we used donepezil, which has a high uptake into the brain (De Vos et al., 2000) . Donepezil
showed potent beneficial actions in the ICS model. It should be noted that the dose required for maximum inhibition of abnormal hyperalgesia and allodynia was 10 μg/kg (i.p.), which was several hundred-times less than that reported to treat dementia in animal models (Saxena et al., 2008) . Similar to pilocarpine, donepezil inhibited ICS-induced thermal hyperalgesia only by i.c.v. injection, and the action by systemic donepezil was antagonized by i.c.v. atropine and pirenzepine. Considering that nicotinic acetylcholine receptor is also known to participate in the pain regulation (Jones and Dunlop, 2007) , further studies are required to elucidate whether donepezil could inhibit ICS-induced hyperalgesia and allodynia via central nicotinic acetylcholine receptors.
On the other hand, it should be noted that pilocarpine-treatment reversed the hyperalgesia and exceeds the normal pain threshold, while donepezil-treatment only reversed it. Although mechanisms underlying different actions of pilocarpine and donepezil remain elusive, it may be interesting to compare the pharmacological mechanisms of both compounds. Because donepezil inhibits degradation of released acetylcholine, the action is presumably confined in the synaptic area, while pilocarpine may have more potential targets, including extrasynaptic receptors, which could be expressed only under pathological situations.
Of importance, systemic or i.c.v. donepezil inhibited ICS-induced hyperalgesia and allodynia for more than 3 h. As shown in Figure 4B , the basal threshold prior to the donepezil treatment at P5 after ICS was approximately 6 s, while it increased to This article has not been copyedited and formatted. The final version may differ from this version. injection (Nishiyori et al., 2011) . Thus, chronic pain in this model may be maintained by vicious cycles, which include the attenuation of a spinally descending, pain inhibitory system and enhancement within pain matrices in the brain. In other words, pain memory may disappear once these vicious cycles are completely lost.
The present study showed that donepezil inhibited ICS-induced fibromyalgia-like pain via supraspinal mechanisms, while it blocks neuropathic pain via spinal mechanisms (Kimura et al., 2013) . Such different pharmacotherapeutical actions against neuropathic pain and ICS-induced fibromyalgia-like pain can be observed in gabapentinoid actions, as described above. We have shown that gabapentin blocks ICS-induced fibromyalgia-like pain via supraspinal mechanisms, while it inhibits nerve injury-induced neuropathic pain via spinal mechanisms (Nishiyori and Ueda, 2008) .
Consistently, a recent clinical neuroimaging study has shown that pregabalin inhibits neuronal connectivity in the brain regions of fibromyalgia patients (Harris et al., 2013) .
Therefore, neuropathic pain and fibromyalgia-like pain may show the difference in the site of donepezil actions, possibly owing to their distinct molecular basis.
Finally, a complete amelioration of using extremely low doses of donepezil would be ideal. However, at the same time, the present successful therapeutic actions of In conclusion, we successfully demonstrated that cholinomimetics, such as pilocarpine and donepezil, inhibited generalized pain syndrome in ICS-exposed mice, which share some pathophysiological and pharmacotherapeutic features with fibromyalgia patients. Repeated treatments with donepezil completely ameliorated the chronic pain, although the lack of morphine analgesia remained even after complete amelioration of pain. As the current criteria of fibromyalgia (Wolfe et al., 2010) uses pain-related somatic symptoms as well as muscle pain, future investigation is necessary to evaluate some more different assessments, such as muscle pain using Randall-Selitto test, according to the report in rats using similar paradigm of ICS/repeated cold stress (Nasu et al., 2010) as well as known tail-flick and hot plate test.
